Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

The extracellular matrix: A dynamic niche in cancer progression

(2012) Pengfei Lu et al.   JOURNAL OF CELL BIOLOGY

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

(2012) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies

(2012) Justin N. Bottsford-Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials

(2012) Diether Lambrechts et al.   LANCET ONCOLOGY

Overcoming Resistance to Antiangiogenic Therapies

(2012) S. Tejpar et al.   ONCOLOGIST

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

(2011) Fotios Loupakis et al.   BMC CANCER

Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

(2011) A. Gerger et al.   CLINICAL CANCER RESEARCH

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab

(2011) D. Lambrechts et al.   EUROPEAN JOURNAL OF CANCER

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

(2011) Peter Carmeliet et al.   NATURE REVIEWS DRUG DISCOVERY

Bevacizumab pharmacogenetics in tumor treatment: still looking for the right pieces of the puzzle

(2011) Guido Bocci et al.   PHARMACOGENOMICS

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer

(2010) J. Pander et al.   ANNALS OF ONCOLOGY

Biomarkers and surrogate end points—the challenge of statistical validation

(2010) Marc Buyse et al.   Nature Reviews Clinical Oncology

Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges

(2009) Sumithra J. Mandrekar et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

(2008) Bryan P. Schneider et al.   JOURNAL OF CLINICAL ONCOLOGY